Clinical Trial Update: GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for ganetespib (GANNET53) in metastatic p53-mutant platinum-resistant ovarian cancer; trial terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Drugs mentioned

• Ganetespib (ganetespib)

Snippet

Sponsor: Medical University Innsbruck | Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-08-13